

Index

A

- 2-Acylamino-4,6-diphenylpyridine, 174–175
- Afferent inputs, 44–45
- Anatomical connections
 - afferent inputs, 44–45
 - efferent projections, 43–44
 - reciprocal connections with GnRH neurons, 45–47
- Antagonists
 - blood–brain barrier, 181
 - clinical applications, 183–184
 - GnRH
 - neuron function, 175–176
 - pulsatility, 176–178
 - secretion, 181–182
 - gonadal steroid negative feedback, 178–180
 - Kiss1* mRNA regulation, 160
 - KP-10 peptide analogues
 - inositol phosphate production, 167–172
 - intracellular calcium release, 167, 172–174
 - leptin stimulation, 183
 - LH ovulatory surge, 180–181
 - peptide development and receptor binding
 - affinity reduction, 161
 - amino acid changes, 163, 166
 - amino acid substitution, 162–166
 - Arg⁹ and Phe¹⁰, 162
 - C-terminus, 161
 - N-terminally truncated peptides, 161
 - Phe⁶, 165
 - RFamides, primary sequences, 164
 - physiological role, 160, 183
 - precursor peptide, 160
 - puberty, role in, 178
 - small molecule, 174–175
- Anteroventral periventricular nucleus (AVPV)
 - estradiol regulation, 280, 281
 - sex steroid regulation, 285–286
- Anteroventral periventricular nucleus/
periventricular nucleus (AVPV/
PeN) *Kiss1* expression
 - gonadal and non-gonadal factors
 - aromatase knockout (ArKO) mice, 233
 - ER α , 234
 - hypogonadal mice, 233
 - ovarian sex steroid secretion, 232–233
 - ontogeny
 - adulthood, 225
 - day of birth/postnatal day 1, 224
 - GnRH appositions, 226
 - immunoreactive cells, 225
 - sexual differentiation
 - in adulthood, 227
 - mRNA levels, 227–228
 - postnatal development, 227, 229
 - sex steroids, 227
 - steroid-mediated sexual differentiation
 - apoptosis, 230
 - CpG methylation, 231, 232
 - epigenetics, 230–231
 - neurogenesis, 229–230
 - physical existence, 230–231
- Anthropogenic EDCs, 458
- Apoptosis, 230
- Arcuate nucleus *Kiss1*
 - estradiol regulation, 280, 281
 - gonadal and non-gonadal factors, 240–243
 - ontogeny

- Arcuate nucleus *Kiss1* (*cont.*)
 apoptosis, 235
 embryonic development, 234
 neonatal stage, 236–237
 PND 1, 235–236
 prepubertal and pubertal changes, 237–238
 sex differences
 adulthood, 239
 neonatal and juvenile, 239–240
 non-rodent species, 240
 sex steroid levels, 238–239
 sex steroid regulation, 286–287
- Arcuate nucleus-kisspeptin/neurokinin B/
 dynorphin neurons (ARC-KNDy)
 gonadectomy induced somatic
 hypertrophy, 353–354
 membrane properties
 castration-induced LH secretion, 353
 ER α expression, 352–353
 GFP expression, 351
 gonadectomy, 351–352
 pulsatility in, 350–351
 reduced firing activity, 353
 neurotransmitter and neuropeptide
 modulation
 GABA, 354
 leptin, 356–358
 neurokinin B, 354–357
 NMDA, 354
- Autosomal recessive inheritance pattern,
 141–143
- B**
- Babinski–Fröhlich syndrome, 4
 Biallelic mutations, 190
 Bisphenol A (BPA)
 human exposure, 479
 rodent kisspeptin system
 females, 466–467
 males, 467–468
- C**
- cAMP responsive element-binding protein-1
 (Creb1)-regulated transcription
 coactivator-1, 374
 Castration-induced LH secretion, 353
 Cell line models. *See* Immortalized cell lines
 Central precocious puberty (CPP), 193–195
 Arg386Pro-KISS1R, 150–151
 autosomal-dominant inheritance mode,
 149–150
 characteristics, 149
 gain-of-function, 152–153
 KISS1R signaling, 151–152
 prevalence, 149
 Chinese Hamster Ovary K1 (CHO-K1) cells,
 114–115
 Cholecystokinin (CCK), 206–207
 Chromosome deletion, 188
 Circadian timing system
 circadian rhythm generation,
 feedbackloops
 CLOCK:BMAL1-mediated
 transcription, 386–387
 SCN, 387
 female reproduction
 hormonal timing, 386
 ovulation and pregnancy maintenance,
 385–386
 preovulatory LH surge and ovulation
 (*see also* Ovulation)
 circadian initiation of, 402–403
 light:dark cycle, 388–389
 locomotor rhythms, 389
 neural mechanisms, 388
 SCN stimulatory signal, 389
 sex steroids, 389
 reproductive aging, 399, 401
 suprachiasmatic nucleus, 386
 temporal communication, 385
 Clinical disorders
 central precocious puberty, 193–195
 fertility phenotypes, 191
 GnRH deficiency, 187–188
 homozygosity mapping
 chromosome localization
 and deletion, 188
 missense mutation, 188–189
KISS1, missing link, 192
 mutations
 biallelic, 190
 discovery, 190–191
 hypogonadotropic hypogonadism,
 189–190
Kiss1^{-/-} and *Kiss1r^{-/-}* mice, 192–193
 Compound 15a, 174, 175
 Compound heterozygous KISS1R mutations,
 145–146
 Compound 91, 174, 175, 181
 CpG methylation, 231, 232

D

- Dynorphin (DYN), 303
 - GnRH pulse generation, 307
 - gonadectomy induced somatic hypertrophy, 353–354
 - membrane properties
 - castration-induced LH secretion, 353
 - ER α expression, 352–353
 - GFP expression, 351
 - gonadectomy, 351–352
 - pulsatility in, 350–351
 - reduced firing activity, 353
 - neurotransmitter and neuropeptide modulation
 - GABA, 354
 - leptin, 356–358
 - neurokinin B, 354–357
 - NMDA, 354
 - stress regulation, 445
- Dystrophia adiposogenitalis, 4

E

- Efferent projections, 43–44
- Electrophysiological approach
 - ARC-KNDy neurons (*see* Arcuate nucleus-kisspeptin/neurokinin B/dynorphin neurons (ARC-KNDy))
 - RP3V-*Kiss1* neurons
 - intrinsic properties, 358
 - neurotransmitter and neuropeptide modulation, 359
- Environmental endocrine disruptors (EDCs)
 - contamination, 457
 - definition, 456
 - environmental sensing
 - anthropogenic EDCs, 458
 - clover disease, 458
 - cytochrome P450 enzymes, 457
 - kisspeptin signaling pathways, 458
 - menstrual cycle irregularities, 458
 - phytoestrogens, 457–458
 - plant alkaloids, 457
 - fetal basis of adult disease hypothesis
 - estrogenic chemicals, 470–471
 - peripheral kisspeptin system, 473
 - puberty, 471–472
 - thrifty phenotype, 479
 - future aspects, 472–473
 - kisspeptin system
 - AVPV/PeN *Kiss1* neurons, 462–463, 465

- bisphenol A, 459
 - genistein, 460–461, 469–470
 - perinatal estrogen, 461–462
 - polychlorinated biphenyls, 459–460
 - in rat, 462–464
 - nuclear estrogen receptors, 458–459
 - plant-derived compounds, 457
 - products, 457
- Epigenetics, 230–231
- Estrogen
 - environmental endocrine disruptor, 461–462
 - E2 signaling, 233, 245
 - feedback system, 279, 282, 286–287
 - seasonal reproduction, 414–416
- Extra-hypothalamic expression, 39–40

F

- Female estrus cycle, 81–82
- Ferguson reflex, 203
- Fertility phenotypes, 191

G

- γ -amino butyric acid (GABA), 121
- Genistein
 - dietary supplements, 460
 - health benefits, 460
 - Kisspeptin system, 469–470
 - in newborns, infants, and adults, 461
- Ghrelin, 375
- Gonadal and non-gonadal factors
 - ARC *Kiss1* expression, 240–243
 - AVPV/PeN *Kiss1* expression
 - aromatase knockout mice, 233
 - ER α , 234
 - hypogonadal mice, 233
 - ovarian sex steroid secretion, 232–233
- Gonadal steroid negative feedback, 178–180
- Gonadectomy induced somatic hypertrophy, 353–354
- Gonadotropin inhibitory hormone (GnIH)
 - circadian-controlled estradiol negative feedback, 398
 - RF-amide-related peptide type-3, 445
 - seasonal breeding
 - antagonist, 420
 - hamsters, 420–421
 - in sheep, 420

- Gonadotropin-releasing hormone (GnRH)
- antagonists
 - neuron function, 175–176
 - pulsatility, 176–178
 - secretion, 181–182
 - deficiency
 - clinical presentation, 187–188
 - KISS1*, missing link, 192
 - KISS1R*, 189–190
 - desensitization effects, 71–72
 - development and reproductive maturation, 80
 - female estrus cycle, 81–82
 - kisspeptin
 - acute central administration, 65
 - acute intraperitoneal administration, 67–68
 - acute intravenous administration, 65–67
 - administration routes, 77–78
 - isoforms, 75–77
 - kisspeptin-54 or rat kisspeptin-52, 64–65
 - repeated administration, 68–70
 - neuronal excitability
 - burst firing in, 124
 - downstream signaling pathways, 115–117
 - Kir channels, 121–122
 - kisspeptin and GnRH secretion, 113–115
 - Kiss1R activation, 115
 - presynaptic effects, 123
 - TRPC channels activation, 117–121
 - nutritional state, 78–79
 - puberty
 - central inhibition, 264–266
 - in juvenile development, 263
 - kisspeptin signaling, 261–262
 - pulsatile infusion, 254–255
 - steroid inhibition, 266–267
 - reciprocal connections, 45–47
 - site of action
 - in brain, 73–74
 - in pituitary, 74–75
- Gonadotropin-releasing hormone (GnRH)
- pulse generator
 - anatomic location
 - GnRH neuronal output, 300–301
 - mediobasal hypothalamus, 300
 - ARC kisspeptin neurons
 - Kiss1r and GnRH axon terminals, 304
 - neural characteristics, 302–303
 - NKB/Dyn neurons, 304
 - NKB/NK3R signaling, 304
 - Dyn/KOR signaling, 307
 - electrophysiological properties, 310
 - gonadal steroids, negative feedback action, 313
 - gonadotropin secretion, 314
 - Kisspeptin/Kiss1r signaling, 307–309
 - LH pulsatile secretion, 298
 - multiple-unit activity
 - ARC kisspeptin neurons, 302
 - GnRH discharge and neuron distribution, 302
 - ovarian steroids and LH secretion, 303
 - sources, 312
 - neurokinin B/kisspeptin interactions
 - autoregulatory loops, 335, 336
 - GnRH secretion, 336
 - kisspeptin release, 335–336
 - KNDy neurons, 336–337
 - signaling, 309–310
 - NKB/NK3R signaling, 305–307
 - pheromones, 314
 - pulse generation
 - erratic LH secretion generated by sustained infusions, 106
 - mechanism, 310–313
 - by single-bolus administration, 104–105
 - pulses and surge discovery, 299
 - secretion, 298
 - stress regulation
 - CORT response, 441–442
 - CRF-R antagonist administration, 441
 - HPG axis, 437
 - hypothalamic amenorrhea, 442
 - insulin-induced hypoglycemia, 438–441
 - LPS stress, 437–439
 - psychological stressors, 441
 - social status, 442
- H**
- Homozygosity mapping
 - chromosome localization and deletion, 188
 - missense mutation, 188–189
- Hormone secretion
 - GnRH pulse generation
 - erratic LH secretion, 106
 - single-bolus administration, 104–105
 - hypothalamic amenorrhea, 106–107

- kisspeptin safety, 107
 - pharmacokinetics
 - challenges in, 91–92
 - kisspeptin-10, 92–93
 - kisspeptin-54, 93–94
 - reproductive endocrine activity stimulation
 - dose responsive gonadotropin secretion, 97–98
 - GnRH deficiency, 101–102
 - GnRH secretion, 102–103
 - hypothalamic amenorrhea, 100–101
 - LH responses, 94–96
 - limitations, 94
 - menstrual cycle, healthy women, 98–100
 - Human kisspeptin-10 (hKP-10), 258–259.
 - See also* KP-10
 - Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, 124
 - Hypogonadotropic hypogonadism, 5, 140–141, 189–190
 - Hypothalamic amenorrhea, 106–107
 - Hypothalamic expression, 39
 - Hypothalamo-pituitary disconnection (HPD), 75
- I**
- Immortalized cell lines
 - advantage, 493
 - future directions, 497
 - GnRH neurons, 494–495
 - intracellular signalling pathways, 493
 - Kiss1* expression, 495
 - limitations of, 495–497
 - migratory inhibition, 493–494
 - PKC α signal disruption, 494
 - Inositol phosphate (IP) production
 - amino acid changes, 168, 171
 - peptide analogues, 168–170
 - Insulin, 376–377
 - Intracellular calcium release, 167, 172–174
- K**
- Kisspeptin
 - in adult brain
 - cell bodies, 31–33
 - fiber, 33–34
 - immunocytochemistry, 28
 - location, 28–30
 - peptide/transmitters, 34–36
 - steroid receptors, 36–37
 - ARC
 - gonadal and non-gonadal factors, 241–243
 - ontogeny, 234–237
 - prepubertal and pubertal changes, 237–238
 - sex differences, 238–240
 - AVPV/PeN
 - gonadal and non-gonadal factors, 232–234
 - ontogeny, 224–226
 - sexual differentiation, 226–229
 - steroid-mediated sexual differentiation, 229–232
 - developmental changes, 243–244
 - expression of, 222–224
 - fibers, 33–34
 - immunoreactivity, 70
 - isoforms, 75–77
 - Kiss1*
 - in females, 47–50
 - and *Kiss2*, functional evolution, 15–16
 - missing link, 192
 - sex steroid regulation (*see* Sex steroid regulation)
 - localization, 222
 - in mammalian brain, 52
 - neuroanatomy (*see* Neuroanatomy)
 - in rodent and non-rodent species, 223
 - structure of, 10–11
- Kisspeptin-54, 115, 258–260
 - Kisspeptin receptor (KISS1R)
 - cellular expression, 40
 - downstream signaling pathways, 115–117
 - extra-hypothalamic expression, 39–40
 - fertility phenotypes, 191
 - hypothalamic expression, 39
 - kisspeptin activation of, 115
 - matches/mismatches of, 40–42
 - mRNA, RT-PCR, 37, 38
 - mutation identification, 188–189
 - physiological role, 160, 183
 - pre-ovulatory LH surge, 180–181
 - puberty onset, 178
 - KP-10
 - functional tests
 - inositol phosphate production, 167–172
 - intracellular calcium release, 167, 172–174
 - peptide antagonist development and receptor binding, 161–167
 - small molecule antagonists, 174–175

L

Lactation, oxytocin role, 202–204. *See also*
Oxytocin

Leptin

ARC-KNDy neurons
Kiss1 mRNA expression, 357
 LepRb expression, 357–358
 nonselective cationic conductance, 358
 pre-mammillary nucleus and POMC
 neuron, 358
 STAT3 signaling, 358
 developmental aspects
 early nutritional manipulation, 375
 early-onset metabolic disorder, 374
 early postnatal overfeeding model,
 374–375
 gestational undernutrition, 374
 postnatal nutritional challenge, 374
 metabolic regulation
 adipocyte hormone, 373
 central leptin treatment, 370–371
 developmental aspects, 374–375
 direct and indirect actions, 372
 GnRH neurons, 370
 gonadectomized ob/ob mice, 371
 hypothalamic amenorrhea, 373
Kiss1 neurons depolarization, 371
 kisspeptin-independent
 mechanism, 373
 puberty and reproduction, 370, 371
 molecular mediators, 373–374
 regulatory functions, 356–357

Luteinizing hormone (LH)

ovulatory surge, 180–181
 pulsatile secretion
 in monkey, 298
 pulse frequency, 298
 in sheep, 299

M

Magnocellular neurosecretory system, 204

Maturation process, 11

Melanin-concentrating hormone (MCH), 376

Melatonin role, seasonal reproduction,
 419–420

Metabolic hormones, 6

Metabolic regulation

food intake and energy balance control,
 377–378
 functional analyses, 368–369
 ghrelin, 375
 insulin, 376–377

Kiss1 mRNA expression

in ARC and AVPV, 366–367
 early-onset overweight and vaginal
 opening, 368
 metabolic stress, kisspeptin-
 immunoreactivity, 367
 negative energy balance, 366
 obesity, 367–368

leptin signaling

adipocyte hormone, 373
 central leptin treatment, 370–371
 developmental aspects, 374–375
 direct and indirect actions, 372
 GnRH neurons, 370
 gonadectomized ob/ob mice, 371
 hypothalamic amenorrhea, 373
Kiss1 neurons depolarization, 371
 kisspeptin-independent
 mechanism, 373
 mTOR signaling, 373–374
 puberty and reproduction, 370, 371
 melanocortins, 376–377
 NPY, 375–376

Missense mutation, 188–189

Model systems

immortalized cell lines
 advantage, 493
 future directions, 497
 GnRH neurons, 494–495
 intracellular signalling pathways, 493
Kiss1 expression, 495
 limitations of, 495–497
 migratory inhibition, 493–494
 PKC α signal disruption, 494
 transgenic mice (*see* Transgenic mice
 generation)

Molecular biology

central precocious puberty
 Arg386Pro-KISS1R, 150–151
 autosomal-dominant inheritance mode,
 149–150
 characteristics, 149
 gain-of-function, 152–153
 KISS1R signaling, 151–152
 prevalence, 149
 KISS1R mutants, 134
 mutational inactivation
 autosomal recessive inheritance pattern,
 141–143
 compound heterozygous KISS1R
 mutations and IHH, 145–146
 frame-shift in KISS1R gene,
 146–147

- hypogonadotropic hypogonadism, 140–141
- Kiss1r disruption mouse models, 148–149
- Leu102Pro KISS1R mutation, 144–145
- Leu148Ser-KISS1R mutation, 141, 144
- not associated with altered function, 147
- Phe272Ser-KISS1R mutation, 145
- onset of puberty, 134
 - Kiss1r expression, 135
 - KISS1R intracellular trafficking, 139–140
 - KISS1R signaling pathway, 136–138
 - pubertal disorders, 135–136
- Mutations
 - autosomal recessive inheritance pattern, 141–143
 - biallelic, 190
 - compound heterozygous KISS1R mutations and IHH, 145–146
 - discovery of, 190–191
 - frame-shift in KISS1R gene, 146–147
 - hypogonadotropic hypogonadism, 140–141, 189–190
 - Kiss1^{-/-}* and *Kiss1r^{-/-}* mice, 192–193
 - Kiss1r disruption mouse models, 148–149
 - Leu102Pro KISS1R mutation, 144–145
 - Leu148Ser-KISS1R mutant and fertility after therapy, 144
 - Leu148Ser-KISS1R mutation, 141, 144
 - not associated with altered function, 147
 - Phe272Ser-KISS1R mutation, 145
- N
- Neuroanatomy
 - anatomical connections
 - afferent inputs, 44–45
 - efferent projections, 43–44
 - reciprocal connections, GnRH neurons, 45–47
 - development and sex differences
 - developmental changes in males, 50
 - Kisspeptin and Kiss1 expression in females, 47–50
 - sexual dimorphism, hormonal control, 50–51
 - distribution in adult brain
 - kisspeptin cell bodies, 31–33
 - kisspeptin fiber, 33–34
 - location, 28–30
 - peptide/transmitters co-localization, 34–36
 - steroid receptors co-localization, 36–37
- Kiss1r distribution
 - cellular expression, 40
 - extra-hypothalamic expression, 39–40
 - hypothalamic expression, 39
 - matches/mismatches of, 40–42
- Neurogenesis, 229–230
- Neurokinin B and neurokinin 3 receptor (NKB/NK3R) system
 - neurokinin B
 - exon encoding, *TAC3* gene, 327
 - neurons in ARC, 327
 - TAC3* and *TAC2* expression, 327, 328
 - tachykinins, 326–327
 - neurokinin 3 receptor
 - in central nervous system, 329
 - gene encoding, 329
 - interactions, 327–328
 - senktide, 328
 - in spinal cord, 329
 - sex steroids
 - estrogen, 329–330
 - organizing effects, 331
 - sexual dimorphism, *Tac2* expression, 330
 - testosterone, 329
- Neurokinin B/Kisspeptin interactions
 - GnRH pulse generation
 - autoregulatory loops, 335, 336
 - GnRH secretion, 336
 - kisspeptin release, 335–336
 - KNDy neurons, 336–337
 - gonadotropin responses to, 333–334
 - Kiss1* neurons
 - GnRH release, 335
 - LH pulse modification, 334
 - reproductive role, 334–335
 - senktide, 334
 - metabolic status, 337–338
 - neurokinin B
 - exon encoding, *TAC3* gene, 327
 - neurons in ARC, 327
 - TAC3* and *TAC2* expression, 327, 328
 - tachykinins, 326–327
 - neurokinin 3 receptor
 - in central nervous system, 329
 - gene encoding, 329
 - potency of affinity, 327–328
 - senktide, 328
 - in spinal cord, 329
 - puberty onset control
 - GnRH release, developmental changes, 337
 - hypothalamic Kiss1 neurons, 337
 - NKB antagonist SB222200, 338
 - sexual maturation, 338
 - Tac2/Tacr3* expression, 337–338

- Neurokinin B (NKB), 303
 electrophysiology studies
 gonadotropin secretion, 356
 KNDy-GDX cells hypertrophy,
 355–356
 NKB depolarization, 354–355
 NK3 receptor antagonist, 356
 voltage-clamp recordings, 355
 Kisspeptin interactions (*see* Neurokinin B/
 Kisspeptin interactions)
- Nucleus of the solitary tract (NTS), 206–207
- Nucleus ventralis tuberis (NVT), 16–17
- O**
- Ontogeny
 ARC *Kiss1* expression
 apoptosis, 235
 embryonic development, 234
 neonatal stage, 236–237
 PND 1, 235–236
 AVPV/PeN *Kiss1* expression
 adulthood, 225
 day of birth/postnatal day 1, 224
 GnRH appositions, 226
 immunoreactive (ir) cells, 225
- Ovulation
 circadian neurochemical communication
 direct SCN signaling, 390–391
 indirect SCN signaling, 391–397
 locomotor and behavioral rhythms,
 389–390
 neural SCN communication, 390
 clock genes and kisspeptin control,
 397–398
 estrogen negative feedback control,
 398–401
 preovulatory LH surge
 circadian initiation of, 402–403
 light:dark cycle, 388–389
 locomotor rhythms, 389
 neural mechanisms, 388
 SCN stimulatory signal, 389
 sex steroids, 389
- Oxytocin
 activation, central kisspeptin
 icv kisspeptin, 212, 214
 in vivo extracellular recordings, 212
 afferent inputs, 206–207
 centrally projecting neurons, 206
 circulating kisspeptin
 activation, by peripheral kisspeptin,
 208–211
 vagal mediation, 210–211
 firing rates, 204–205
 magnocellular neurosecretory system, 204
 parturition, 203
 roles of, 202–204
- P**
- Paraventricular nucleus (PVN), 204
- Parturition, oxytocin regulation in, 203
- Peptide antagonists
 development and receptor binding
 amino acid substitution, 162–166
 C-terminus, 161
 N-terminally truncated peptides, 161
 RFamides, primary sequences, 164
 functional tests
 inositol phosphate production,
 167–172
 intracellular calcium release, 167,
 172–174
- Pharmacokinetics
 challenges, 91–92
 kisspeptin-10, 92–93
 kisspeptin-54, 93–94
- Phylogeny
 gpr54-1 and gpr54-2, 14–15
 Kiss1 and Kiss2 genes, 11–13
 RFamide peptide family, 20–21
- Phytoestrogens
 endocrine disruption, 457–458
 genistein
 dietary supplements, 460
 health benefits, 460
 Kisspeptin system, 469–470
 in newborns, infants, and adults, 461
 roles of, 456
- Polychlorinated biphenyls
 physical and chemical properties, 459
 rodent kisspeptin system
 females, 468–469
 males, 469
 uses, 459–460
- Polycystic ovarian syndrome (PCOS), 184
- Posterior-anterior deafferentation (PAD), 300
- Pregnancy
 circadian timing system, 385–386
 oxytocin role, 202–204 (*see also*
 Oxytocin)
- Programmed cell death. *See* Apoptosis
- Proopio-melanocortin (POMC) neurons, 376
- Puberty. *See also* Central precocious
 puberty (CPP)
 antagonists role in, 178
 ARC *Kiss1* expression, 237–238

- gonadotropin-releasing hormone
 - central inhibition, 264–266
 - in juvenile development, 263
 - kisspeptin signaling, 261–262
 - pulsatile infusion, 254–255
 - for steroid inhibition, 266–267
 - kisspeptin neuronal system
 - cell growth, 257
 - developmental assessment, 257
 - GnRH release, 259
 - gonadal steroids circulation, 259, 261
 - Kiss1* mRNA expression, 256
 - kisspeptin-54 release, 258–260
 - postnatal development, 257–258
 - timing control model, 263
 - neuronal substrates
 - central inhibition, 264–266
 - for steroid inhibition, 266–267
 - onset control
 - GnRH release, developmental changes, 337
 - hypothalamic *Kiss1* neurons, 337
 - NKB antagonist SB222200, 338
 - sexual maturation, 338
 - Tac2/Tacr3* expression, 337–338
- R**
- Reproductive endocrine activity stimulation
 - GnRH
 - deficiency, 101–102
 - in men, 97–98
 - secretion, 102–103
 - hypothalamic amenorrhea, 100–101
 - LH responses, kisspeptin, 94–96
 - menstrual cycle in healthy women
 - early follicular phase, 100
 - mid-follicular phase, 98, 99
 - mid-luteal phase, 99
 - RF-amide-related peptide type-3 (RFRP-3), 398, 445–446
- S**
- Seasonal reproduction
 - A14/A15 dopaminergic nucleus, 418–419
 - breeding and nonbreeding seasons, 421
 - CLOCK gene expression, 411
 - GnRH secretion control, 411–412
 - gonadotropin inhibitory hormone antagonist (RF9), 420
 - hamsters, 420–421
 - in sheep, 420
 - kisspeptin
 - in arcuate nucleus, 413–414
 - castration and testosterone replacement, 416–417
 - estrogen feedback effects, 414–416
 - light/dark cycle, 418
 - NKB expression, 416
 - in preoptic area, 413–414
 - in sheep, 417–418
 - melatonin role in, 419–420
 - photoperiodic quiescence
 - GnRH/gonadotropic axis stimulation, 422–423
 - kisspeptin-10 infusion, 422–424
 - preovulatory LH surge, 421–422
 - Sex steroid receptors, hypothalamus, 304
 - Sex steroid regulation
 - estrogen negative feedback, 279, 282
 - Kiss1*
 - differential regulation, 287–289
 - distribution, 276–277
 - in females, 279–282
 - HPG sensitivity, 289–290
 - in males, 282–283
 - kisspeptin
 - ARC and POA in ovine species, 286–287
 - AVPV in rodent species, 285–286
 - feedback control, 277–278
 - missing link, GnRH secretion, 278–279
 - negative feedback regulation, 284
 - physiological role, 276–277
 - testosterone, 282
 - Sexual differentiation
 - ARC *Kiss1* expression
 - adulthood, 239
 - neonatal and juvenile, 239–240
 - non-rodent species, 240
 - sex steroid levels, 238–239
 - AVPV/PeN *Kiss1* expression
 - in adulthood, 227
 - mRNA levels, 227–228
 - postnatal development, 227, 229
 - sex steroids, 227
 - developmental changes in males, 50
 - Kisspeptin expression in females, 47–50
 - sexual dimorphism, hormonal control, 50–51
 - Small molecule antagonists, 174–175
 - Steroid inhibition, 266–267
 - Steroid sensitivity
 - in mammals, 16
 - nonmammalian species, 16–17
 - in vertebrates, 17–18

Stress regulation

- GnRH pulse generator
 - CORT response, 441–442
 - CRF-R antagonist administration, 441
 - HPG axis, 437
 - hypothalamic amenorrhea, 442
 - insulin-induced hypoglycemia, 438–441
 - LPS stress, 437–439
 - psychological stressors, 441
 - social status, 442
- immunological stress, 432
- kisspeptin-expressing neurons, 432
- metabolic stress, 432
- networks and kisspeptin signaling
 - CGRP neurons, 445
 - CRF signaling, 443–445
 - Dyn analog, 445
 - GABAergic transmission, 446
 - pulsatile LH secretion
 - suppression, 444
 - RFRP-3 administration, 445–446
 - stress-induced CORT feedback, 443
- puberty
 - advanced, 433
 - CRF expression, 435
 - CRF-R1 and CRF-R2, 435, 436
 - delayed, 433
 - environmental factors, 433
 - Kiss1r* signaling, 433
 - limbic brain, 435
 - mPOA and ARC, neural inputs, 435
 - neonatal lipopolysaccharide, 433–434
 - overnutrition, 433
 - PVN neural cell line, 435–436
- Supraoptic nucleus (SON), 204

T

- Tachykinins, 326–327
- Testosterone, 282
- Transducer of Regulated Creb (TORC1), 374
- Transgenic mice generation
 - conditional gene ablation, 490
 - embryonic stem modification, 483
 - with fluorescently-marked GnRH neurons, 491–493
 - with fluorescently-marked *Kiss1* neurons, 493
- future directions, 497
- genetic ablation
 - GnRH neurons, 490–491
 - Kiss1* neurons, 491
- Kiss1* disruption, 483–484
- Kiss1r* and *Kiss1* mutant mice phenotypes
 - mutant mice lines, 484, 487
 - partial sexual maturation, 487
 - phenotypic differences, 487, 488
 - pre-ovulatory LH surge, 487
 - vaginal keratinization, 487
- Kiss1r* disruption, 483, 484
- tagged *Kiss1r* and *Kiss1* alleles
 - Cre/Gfp* fusion gene, 488–489
 - IRES-Cre transgene, 488
 - Tg(Kiss1-Cre)J2-4Cfe* line, 489–490
- transgenic lines, 485–486
- Transient receptor potential channels (TRPC), 117–121
- T-type calcium channels, 124

V

- Vasoactive intestinal polypeptide (VIP), 390–391
- Ventrolateral medulla (VLM), 206–207